Synairgen Share Discussion Threads

[jev1] 29/3/2020 19:02

Talk2dubya

_______

The study has been designed to maximize the likelihood that

as much data as possible is collected and shared rapidly

in a format that can be easily aggregated, tabulated and analysed across many different settings

globally.

_______

Is this what you're referring to ?

[talk2dubya] 29/3/2020 18:47

I think there is actually another big hint in that NHS link (you need to change htxxs to http to get it to work). Be interested to see if anyone else can see the same as me.

[bigman786] 29/3/2020 18:25

I was totally unaware of this Co until just reading about it in the Sunday Times. Fingers and everything else crossed that's it successful and patients can be treated.

[talk2dubya] 29/3/2020 18:04

From the testing RNS:

Since the outbreak of COVID-19, Synairgen has been approached by, and is in discussion with, a number of other medical, scientific, and Governmental bodies (both in the UK, US and internationally) seeking to investigate novel therapeutics in this area.



Join the dots.

[talk2dubya] 29/3/2020 18:02

hxxps://www.uhs.nhs.uk/ClinicalResearchinSouthampton/Research/COVID-19/COVID-19-studies.aspx


SG016

A randomised double-blind placebo-controlled trial to determine the safety and efficacy of inhaled SNG001 (IFN-β1a for nebulisation) for the treatment of patients with confirmed SARS-CoV-2 infection.

COVIPOC

Biofire rapid diagnostics in COVID-19


From the article above:

BIOFIRE® COVID-19 test detects SARS-CoV-2 in approximately 45 minutes from a nasopharyngeal swab in transport media. This test runs on the fully automated FILMARRAY® 2.0 and FILMARRAY® TORCH platforms and is extremely easy to use, therefore requiring minimal training and skills in molecular biology.

BIOFIRE® COVID-19 was developed with funding from the U.S. Department of Defense (DoD) by leveraging an existing contract agreement with BioFire Defense. This is the second of three tests being developed for diagnostic use as part of bioMérieux’s strategic response to the COVID-19 pandemic.



Test and treat.

[talk2dubya] 29/3/2020 17:54

P6 of the attached for those who are unaware of the link

hxxps://www.synairgen.com/wp-content/uploads/2019/07/Corporate-presentation-July-2019-v2.pdf

[talk2dubya] 29/3/2020 17:53

Ha - that’s great news.

[nobbygnome] 29/3/2020 17:49

Great find timbo!

[timbo003] 29/3/2020 17:49

I see bioMérieux are pushing ahead with expanding the biofire respiratory panel to include COVID 19 (March 24th) as well as developing a standalone test (March 11th).



RM has previously described the introduction of biomerieux's biofire as a game changer for the Synairgen clinicals, as it not only establishes whether the patients have a viral infection or not, but it also identifies which pathogen(s) is involved.

Needless to say, getting COVID onto the biofire respiratory panel would certainly assist the (suspended) COPD study (which already uses the biofire respiratory panel to screen patients for virus infection) once it recommences. Furthermore looking ahead, it should be extremely helpful for screening patients rapidly and accurately for all future SNG001 COVID studies.

[makendon] 29/3/2020 17:08

Tidy2

Worth noting that it was from today’s edition of the Sunday Times :)

[tidy 2] 29/3/2020 16:24

Sunday Times Article in full BUY SynairgenThe Times article today reposted for anyone yet to see.As the world's top scientists and drugs giants strive to develop vaccines and experimental drugs to fight Covid-19, a little-known British company is already racing to the front line.Synairgen, listed on the London Stock Exchange and worth just £50m, is starting a clinical trial in hospitals across the UK with a drug it hopes will prevent coronavirus sufferers from falling seriously ill.Synairgen's technology uses a naturally occurring protein known as interferon beta, which orchestrates the body's antiviral response. It is used as a treatment for multiple sclerosis.Synairgen's team of experts has turned it into a drug that can be delivered through an inhaler. By boosting the lung's defence mechanisms, it is hoped the drug - known as SNG001 - will prevent patients from developing severe lower respiratory tract illnesses caused by infections such as Covid-19. Phase II trials in patients with asthma have already shown that it enhances the lung's antiviral defences.Synairgen will now test the treatment on 100 patients with coronavirus. Half will be given its new drug, half will get a placebo. Results could arrive in as soon as eight weeks, which could pave the way for a fast-tracked pivotal study in a bigger group of patients and rapid approval.A treatment could finally bring success for Synairgen. Since listing in 2004, its shares had fallen more than 95% - hit by a lack of funding and an overhang from investors including fallen stockpicker Neil Woodford. While shares in most of Britain's biggest companies have taken a hammering since the outbreak began, Synairgen's have climbed more than 300%, closing on Friday at 46p and giving the company a value of £50.3m.The run gave Synairgen the confidence last week to announce a £14m share placing, which brought in new investors including Polar Capital, while hedge fund Lansdowne increased its holding.Directors also bought shares, which were issued at 35p each - a 32% discount to the closing price on the day before the placing was announced. The new money will provide enough cash to complete the trial and start manufacturing the drug, should it be approved.For patients with pre-existing health conditions such as asthma, who are more at risk of complications from Covid-19, Synairgen could be on to a key treatment. Clinical trials are notoriously high-risk, but existing data shows its drug is well tolerated. Synairgen should have a part to play in the fightback against the pandemic. Buy

[pdt] 29/3/2020 15:03

Thanks for posting makendon.

However ...



"Hydroxychloroquine, a more tolerable form of chloroquine, didn’t top placebo at clearing the coronavirus among mild Chinese patients, or helping them reach normal temperature sooner, Evercore ISI analyst Umer Raffat noted in a Tuesday memo".

There is more detail in the article but it doesn't sound like a game changer to me.

[makendon] 29/3/2020 13:35

Using my newly learned skill, I’ve uploaded the BBC feature on YouTube
:

[makendon] 29/3/2020 13:19

BBC news. I think you may be able to catch it ( not the virus) on iPlayer

[torreskid] 29/3/2020 12:48

guys which channel? BBC one or BBC NEWS?

[freedosh] 29/3/2020 12:47

He’s not a geologist. He’s a very naughty boy
lithological heterogeneities
Intermittently stoned.

[hazl] 29/3/2020 12:33

BBC Political tool US American stuff!
Annoying .
At least the S TIMES have brought us to peoples knowledge.
At least the man interviewed about the Malaria drug was very honest about the drug.

[arpy2] 29/3/2020 12:30

I just watched the BBC news at 12 and around 12:15 for about 5 minutes was the featured about trials. The expert was a bit downbeat to say the least and ultra cautious and was only willing to endorse paracetamol. Not brilliant but I'd like to hear other peoples opinions.

[makendon] 29/3/2020 12:07

BBC news at 12 will feature a section on potential cures - tune in if you can

[toffeeman] 29/3/2020 11:29

I presume you are a geologist - I study consumer heterogeneity :)

[lithological heterogeneities] 29/3/2020 11:20

no problems Toffee.
no apology needed whatsoever.